These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 25890085)
1. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085 [TBL] [Abstract][Full Text] [Related]
2. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. Zhang P; Garnett J; Creighton CJ; Al Sannaa GA; Igram DR; Lazar A; Liu X; Liu C; Pollock RE J Pathol; 2014 Feb; 232(3):308-18. PubMed ID: 24132643 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160 [TBL] [Abstract][Full Text] [Related]
5. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665 [TBL] [Abstract][Full Text] [Related]
6. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2. Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878 [TBL] [Abstract][Full Text] [Related]
7. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p. Mody HR; Hung SW; AlSaggar M; Griffin J; Govindarajan R Mol Cancer Res; 2016 Nov; 14(11):1124-1135. PubMed ID: 27624777 [TBL] [Abstract][Full Text] [Related]
9. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591 [TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284 [TBL] [Abstract][Full Text] [Related]
11. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Li Z; Wang Y; Qiu J; Li Q; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Yang J; Cheng J Oncotarget; 2013 Dec; 4(12):2532-49. PubMed ID: 24345883 [TBL] [Abstract][Full Text] [Related]
12. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis. Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657 [TBL] [Abstract][Full Text] [Related]
14. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519 [TBL] [Abstract][Full Text] [Related]
15. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Zhang H; Zhang H; Zhao M; Lv Z; Zhang X; Qin X; Wang H; Wang S; Su J; Lv X; Liu H; Du W; Zhou W; Chen X; Fei K Cell Physiol Biochem; 2013; 31(1):56-65. PubMed ID: 23343715 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151 [TBL] [Abstract][Full Text] [Related]
17. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Smits M; Nilsson J; Mir SE; van der Stoop PM; Hulleman E; Niers JM; de Witt Hamer PC; Marquez VE; Cloos J; Krichevsky AM; Noske DP; Tannous BA; Würdinger T Oncotarget; 2010 Dec; 1(8):710-20. PubMed ID: 21321380 [TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167 [TBL] [Abstract][Full Text] [Related]
19. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567 [TBL] [Abstract][Full Text] [Related]
20. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Riquelme E; Suraokar M; Behrens C; Lin HY; Girard L; Nilsson MB; Simon G; Wang J; Coombes KR; Lee JJ; Hong WK; Heymach J; Minna JD; Wistuba II Clin Cancer Res; 2014 Jul; 20(14):3849-61. PubMed ID: 24850841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]